Rajeshwar Rao Tekmal
Overview
Explore the profile of Rajeshwar Rao Tekmal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nair H, Kirma N, Ganapathy M, Vadlamudi R, Tekmal R
Steroids
. 2011 Apr;
76(8):792-6.
PMID: 21477609
Treatment with anti-estrogens or aromatase inhibitors (AI) is the main therapeutic strategy used against estrogen receptor ERα-positive breast cancer. Resistance to these therapies presents a major challenge in the management...
12.
Vallabhaneni S, Nair B, Cortez V, Challa R, Chakravarty D, Tekmal R, et al.
Breast Cancer Res Treat
. 2010 Dec;
130(2):377-85.
PMID: 21184269
The estrogen receptor (ER) is implicated in the progression of breast cancer. Despite positive effects of hormonal therapy, initial or acquired resistance to endocrine therapies frequently occurs. Recent studies suggested...
13.
Nair B, Nair S, Chakravarty D, Challa R, Manavathi B, Yew P, et al.
Cancer Res
. 2010 Sep;
70(18):7166-75.
PMID: 20807815
Estrogen receptor (ER) signaling plays an important role in breast cancer progression, and ER functions are influenced by coregulatory proteins. PELP1 (proline-, glutamic acid-, and leucine-rich protein 1) is a...
14.
Chakravarty D, Nair S, Santhamma B, Nair B, Wang L, Bandyopadhyay A, et al.
Cancer Res
. 2010 May;
70(10):4092-101.
PMID: 20460518
The molecular basis of breast cancer progression to metastasis and the role of estrogen receptor (ER) signaling in this process remain poorly understood. Emerging evidence suggests that ER participates in...
15.
Chakravarty D, Tekmal R, Vadlamudi R
IUBMB Life
. 2009 Dec;
62(3):162-9.
PMID: 20014005
Recent studies implicate that the estrogen receptor (ER) coregulator proline-, glutamic acid-, and leucine-rich protein (PELP) 1 as playing critical roles in ER-genomic, ER-nongenomic, and ER-signaling cross talk with growth...
16.
Vadlamudi R, Rajhans R, Chakravarty D, Nair B, Nair S, Evans D, et al.
J Steroid Biochem Mol Biol
. 2009 Oct;
118(4-5):211-8.
PMID: 19800002
Estradiol (E2), estrogen receptor (ER), ER-coregulators have been implicated in the development and progression of breast cancer. In situ E2 synthesis is implicated in tumor cell proliferation through autocrine or...
17.
Veerapaneni P, Kirma N, Nair H, Hammes L, Hall K, Tekmal R
Gynecol Oncol
. 2009 Jun;
114(3):496-500.
PMID: 19555998
Objectives: We have previously demonstrated that aromatase mRNA is induced in cervical carcinomas compared to normal tissue, suggesting that in situ aromatase expression leading to elevated local estrogen production may...
18.
Hammes L, Tekmal R, Naud P, Edelweiss M, Kirma N, Valente P, et al.
Gynecol Oncol
. 2008 Jun;
110(3):445-51.
PMID: 18565574
Objectives: To describe the expression of vascular endothelial growth factor (VEGF), proto-oncogene macrophage colony-stimulating factor receptor (c-fms) and cyclooxygenase-2 (COX-2) in cervical carcinogenesis and to analyze the correlation of VEGF...
19.
Dimple C, Nair S, Rajhans R, Pitcheswara P, Liu J, Balasenthil S, et al.
Cancer Res
. 2008 Jun;
68(12):4902-9.
PMID: 18559538
Emerging evidence suggests that nuclear receptor (NR) coregulators have potential to act as master genes and their deregulation can promote oncogenesis. Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1/MNAR) is a...
20.
Nagpal J, Nair S, Chakravarty D, Rajhans R, Pothana S, Brann D, et al.
Mol Cancer Res
. 2008 May;
6(5):851-61.
PMID: 18505929
PELP1 (proline-rich, glutamic acid-rich, and leucine-rich protein-1) is a potential proto-oncogene that functions as a coregulator of estrogen receptor (ER), and its expression is deregulated during breast cancer progression. Emerging...